Product Licence Number	*Company Name*	*Product Name*	*Active Ingredients*	*Indications (Non-Prescriptive Items)*	*Date of Authorisation*
			Cinnamaldehyde, Oak Moss HSE 0·43 6. Colophony+ HSE 0·85 7. Epoxy Resin (DER 331) HSE 0·05 8. Thiuram Mixture HSE 0·025 Equal amounts by weight of: Tetramethltaiuram Monosulphide Tetraethylthiuram Disulphide Tetraethylthiuram Disulphide+ Dipentamethylenethiuram Disulphide HSE 0·025 9. Balsam of Peru HSE 0·8 10. Ethylene Diamine Dihydrochloride HSE 0·05 11. Cobalt Dichloride++ HSE 0·02		
0010/0174	Bayer UK Limited t/a Bayer UK Limited Pharmaceutical Business Group	Adalat La 30 mg Tablets	Nifedipine (Microfine) USP 30 mg	POM	16th March 1992
0010/0175	Bayer UK Limited t/a Bayer UK Limited Pharmaceutical Business Group	Adalat LA 60mg Tablets	Nifedipine (Microfine) USP 60mg	POM	16th March 1992
0010/0176	Bayer UK Limited t/a Bayer UK Limited Pharmaceutical Business Group	Adalat LA 90mg Tablets	Nifedipine (Microfine) USP 90mg	POM	16th March 1992
0011/0163	John Wyeth & Brother Limited t/a Wyeth Laboratories	Premarin Vaginal Cream	Conjugated Oestrogens, Concentrate of 18 mg Activity per gram USP 34·72 mg	POM	22nd November 1990
0011/0173	John Wyeth & Brother Limited t/a Wyeth Laboratories	Isordil Tablets 10 mg	Isosorbide Dinitrate/ Lactose Blend 25% BP 40·0 mg Equivalent to 10 mg Isosorbide Dinitrate	For the Prophylactic Treatment of Angina (Classic Effort Associated Angina, Chronic Stable Angina, Vasospastic Angina, Unstable Angina and Angina Decubitus). Acute and Chronic Congestive Heart Failure including that associated with Myocardial Infarction as Adjunctive Therapy. *Route of Administration:* Oral. PM	5th September 1990
0011/0174	John Wyeth & Brother Limited t/a Wyeth Laboratories	Isordil Tablets 30 mg	Isosorbide Dinitrate/ Lactose Blend 25% BP 120·0 mg Equivalent to 30 mg Isosorbide Dinitrate	For the Prophylactic Treatment of Angina (Classic Effort Associated Angina, Chronic Stable Angina, Vasaopastic Angina, Variant Angina, Unstable Angina and Angina Decubitus). Acute and Chronic Congestive Heart Failure including that associated with Myocardial Infarction as Adjunctive Therapy. *Route of Administration:* Oral. PM	5th September 1990